Related Experiment Video
Updated: Jul 29, 2025
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations
Neil Vargesson1, Geoffrey Hooper2, Grey Giddins3
1School of Medicine Medical Sciences & Nutrition. Institute of Medical Sciences. University of Aberdeen. Aberdeen, UK.
Insights
Thalidomide embryopathy, a birth defect, still poses risks despite the drug
Area of Science:
- Developmental biology
- Teratology
- Medical history
Background:
- Thalidomide caused severe limb defects (embryopathy) when used in the 1950s-60s.
- Despite its withdrawal, thalidomide is now re-licensed for specific conditions like cancers and inflammatory disorders.
- Unsafe use can still lead to embryonic damage.
Purpose of the Study:
- To provide a comprehensive review of thalidomide upper limb embryopathy.
- To discuss pathogenesis, historical and current management strategies for pediatric and adult patients.
- To raise awareness of age-related changes in individuals with limb differences and inform care.
Main Methods:
- Literature review of thalidomide embryopathy.
- Analysis of historical and contemporary management approaches.
- Examination of age-related changes and future therapeutic directions.
Main Results:
- Thalidomide's teratogenic effects on limb development are well-documented.
- Current thalidomide use requires strict safety protocols to prevent embryo exposure.
- Thalidomide analogues with reduced teratogenicity show promise.
Conclusions:
- Understanding thalidomide embryopathy is crucial for managing survivors.
- Awareness of age-related issues aids surgical and medical support for limb differences.
- Principles of care for thalidomide survivors can inform management of other congenital limb differences.
Abstract:
This review article provides a comprehensive overview of thalidomide upper limb embryopathy including updates about its pathogenesis, a historical account of the management of the paediatric thalidomide patient, experience with management of the adult patient, as well as creating awareness about early onset age-related changes associated with limb differences. Despite its withdrawal from the market in November 1961, novel discoveries have meant thalidomide is licensed again and currently still in use to treat a variety of conditions, including inflammatory disorders and some cancers. Yet, if not used safely, thalidomide still has the potential to cause damage to the embryo. Recent work identifying thalidomide analogues that retain clinical benefits yet without the harmful effects are showing great promise. Understanding the problems thalidomide survivors face as they age can allow surgeons to support their unique healthcare issues and translate these principles of care to other congenital upper limb differences.
More Related Videos
17:28Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
09:51Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators
Published on: March 21, 2018
